Evidence map›Paper›PMID 39434162›Full record

ArticleJournal of orthopaedic surgery and research2024

Kaempferol promotes osteogenic differentiation in bone marrow mesenchymal stem cells by inhibiting CAV-1.

Yingxue Li, Ying Wang, Qian Liu, Shuiying Lv, Yali Wang, Huanhuan Zhang, Qiuhong Zhao, Lei Shang

Abstract read
In one paragraph

Article in Journal of orthopaedic surgery and research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. [Mechanism of sodium valproate in inhibiting ferroptosis of bone marrow mesenchymal stem cells via the adenosine monophosphate-activated protein kinase/Sirtuin 1 axis].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2025
    Article
  7. Frontiers in pharmacology · 2025
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yingxue Li7th Ward, Department of Rheumatology and Immunology, Xi'an No.5 Hospital, Xi'an, 710082, Shaanxi, P.R. China.
Ying Wang5th Ward, Department of Rheumatology and Immunology, Xi'an No.5 Hospital, Xi'an, 710082, Shaanxi, P.R. China.
Qian Liu5th Ward, Department of Rheumatology and Immunology, Xi'an No.5 Hospital, Xi'an, 710082, Shaanxi, P.R. China.
Shuiying Lv7th Ward, Department of Rheumatology and Immunology, Xi'an No.5 Hospital, Xi'an, 710082, Shaanxi, P.R. China.
Yali WangDepartment of Traditional Chinese Medicine, Xi'an International Medical Center Hospital, No. 777, Xitai Road, High-tech Zone, Xi'an, 710117, Shaanxi, P.R. China.
Huanhuan ZhangChinese Medicine Pharmacy, Xi'an International Medical Center Hospital, Xi'an, 710117, Shaanxi, P.R. China.
Qiuhong ZhaoDepartment of Pharmacy, Xi'an International Medical Center Hospital, Xi'an, 710117, Shaanxi, P.R. China.
Lei ShangDepartment of Traditional Chinese Medicine, Xi'an International Medical Center Hospital, No. 777, Xitai Road, High-tech Zone, Xi'an, 710117, Shaanxi, P.R. China. shanglei_7548@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveOur study focused on the effects and molecular mechanisms of kaempferol, a major active component of Eucommia ulmoides Oliver (EUO), on the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs).

methodsTarget molecules for EUO, osteoarthritis, and osteogenic differentiation were identified through network pharmacology analysis. BMSCs were isolated and treated with various concentrations of kaempferol. Optimal concentration was determined through MTT assays. Osteogenic differentiation was assessed using alkaline phosphatase (ALP) and Alizarin Red S staining, while osteogenic markers (Collagen I, RUNX2, and OPN) and CAV-1 expression were analyzed using RT-qPCR and Western blot. The effects of combined treatment with kaempferol and an overexpression vector for CAV-1 (oe-CAV-1) on osteogenic differentiation were also observed.

resultsNetwork pharmacology analysis identified kaempferol as the primary active component influencing CAV-1 targeted in subsequent experiments. It was found that 10 µM kaempferol was optimal for treating BMSCs. Post-treatment, significant increases in ALP activity and calcium deposition were observed, along with elevated expression of osteogenic markers, and decreased CAV-1. Overexpression of CAV-1 significantly reversed the promotive effects of kaempferol on BMSC osteogenic differentiation, effectively inhibiting the process.

conclusionCollectively, kaempferol promotes osteogenic differentiation in BMSCs by inhibiting CAV-1 expression.

Indexed as

Caveolin 1Cell DifferentiationKaempferolsMesenchymal Stem CellsOsteogenesisAnimalsBone Marrow CellsCells, CulturedRats, Sprague-DawleyCaveolin 1kaempferolKaempferolsBone marrow mesenchymal stem cellsCAV-1KaempferolOsteogenic differentiation

Identifiers

PMID39434162
PMCPMC11495062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.